The criteria required for an effective screening strategy for osteoporosis are largely met in Caucasian women. The disease is common and readily diagnosed by the measurement of bone mineral with single- or dual-energy absorptiometry. Such measurements have high specificity but lower sensitivity, so that the value of the technique is greater for those identified as being at higher risk. Against this background there is little evidence that osteoporosis can usefully be tackled by a public health policy to influence risk factors such as smoking, exercise and nutrition. This suggests that it is appropriate to consider targetting of treatment with agents affecting bone metabolism to susceptible individuals. Since the main benefits of the use of hormone replacement therapy (HRT) are probably on cardiovascular morbidity, the major role for selective screening is to direct non-HRT interventions. An appropriate time to consider screening and intervention is at the menopause, but screening at later ages is also worthy of consideration. Since the cost of screening is low and that of bone-active drugs is high, the selective use of screening techniques will improve the cost-benefit ratio of intervention.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Grisso JA, Baum CR, Turner BJ. What do physicians in practice do to prevent osteoporosis? J Bone Miner Res 1990;5:213–9.
Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. BMJ 1991;302:1317–20.
Griffin J, Robinson R. Hormone replacement for osteoporosis. Lancet 1990;335:1163.
Peck WA, Barrett-Connor E, Buckwalter JA, et al. Osteoporosis: NIH Consensus Development Conference statement. JAMA 1984;252:799–802.
Anonymous. Consensus development conference: prophylaxis and treatment of osteoporosis. BMJ 1989;295:914–17.
Anonymous. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107–10.
Anonymous. Consensu development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646–50.
Law MR, Wald NJ, Meade TW. Strategies for prevention of osteoporosis and hip fracture. BMJ 1991;303:453–9.
Pitt FA, Lloyd-Jones M, Brazier JE, McGrother CW, Kanis JA, Wallace WA, Jones K. The costs and benefits of screening and preventing postmenopausal osteoporosis in the Trent Region. Report of the Trent Osteoporosis Working Group 1990.
Cooper C, Shah S, Hand DJ, Adams J. Compston J, Davie M, Woolf A. Screening for vertebral osteoporosis using individual risk factors. Osteoporosis Int 1991;2:48–53.
Hoffenberg R, James OFW, Brocklehurst JC, Green ID, Hor-rocks P, Kanis JA, et al. Fractured neck of femur: prevention and management. J R Coll Physicians Lond 1989;23:8–12.
Freemantle N. Screening for osteoporosis to prevent fractures. In: Effective health care no. 1. School of Public Health, Leeds, 1992.
Sackett DL, Holland WW. Controversy in the detection of disease. Lancet 1975;2:357–9.
World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series. Geneva: WHO, 1994.
Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res, in press, 1994.
Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med 1991;115:837–42.
Melton LJ. Epidemiology of fractures. In: Riggs BL, Melton LJ III, editors. Osteoporosis: etiology, diagnosis, and management. New York: Raven Press, 1988:133–54.
Johnell O, Gullberg B, Allander E, Kanis JA. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporosis Int 1992;2:298–302.
Winner SJ, Morgan CA, Evans JG. Perimenopausal risk of falling and incidence of distal forearm fracture. BMJ 1989;298:1486–8.
Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Miner Res 1992;7:1005–10.
Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178–208.
Lauritzen JB, Schwarz P, Lund B, McNair P, Transbol I. Changing incidence and lifetime risk of common osteoporosis related fractures: Hvidovre Osteoporosis Study. Osteoporosis Int 1993;3:127–32.
Versluysen M. How elderly patients with femoral fracture develop pressure sores in hospital. BMJ 1986;292:1311–3.
Miller CW. Survival and ambulation following hip fracture. J Bone Joint Surg [Am] 1978;60:930–4.
Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026–32.
Phillips S, Fox N, Jacobs J, Wright WE. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988;9:271–9.
Nydegger V, Rizzoli R, Rapin C-H, Vasey H, Bonjour J-P. Epidemiology of fractures of the proximal femur in Geneva: incidence, clinical and social aspects. Osteoporosis Int 1991;2:42–7.
de Bruijn HP. The Colles' fracture: review of literature. Acta Orthop Scand 1987;58 (Suppl 223):7–25.
Wadsworth TG. Colles' fracture: failure in management may cause permanent disability. BMJ 1990;301:192–4.
Atkins RM, Duckworth T, Kanis JA. The features of algodystrophy following Colles' fracture. J Bone Joint Surg [BR] 1990;72:105–10.
Melton LJ, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporosis Int 1993;3:113–9.
Ettinger B, Black DM, Nevitt MC, Rundle AC, Cauley JA, Cummings SR, Genant HK and the Study of Osteoporotic Fractures Research Group. Contribution of vertebral deformities to chronic back pain and disability. J Bone Miner Res 1992;7:449–56.
Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992;13:S1–10.
Peck WA, Riggs BL, Bell NH, Wallace RB, Johnston CC Jr, Gordon SL, Shulman LE. Research directions in osteoporosis. Am J Med 1988;84:275–82.
Kanis JA, Pitt F. Epidemiology of osteoporosis. Bone 1992;31(Suppl 1):S7–15.
Levy E. Cost analysis of osteoporosis related to untreated menopause. Clin Rheumatol 1989;8(Suppl 2):76–82.
Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 1992;2:285–9.
Melton LJ, O'Fallon WM, Riggs BL. Secular trends in the incidence of hip fractures. Calcif Tissue Int 1987;41:57–64.
Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990;263:2335–40.
Naessen T, Persson I, Adami H-O, Bergstrom R, Berqvist L. Hormone replacement therapy and the risk for first hip fracture. Ann Intern Med 1990;113:95–103.
Rehnberg L, Nungu S, Olerud C. The incidence of femoral neck fractures in women is decreasing [Abstract]. Acta Orthop Scand 1992;63(Suppl 248):92–3.
Spector TD, Cooper C, Fenton Lewis A. Trends in admissions for hip fracture in England and Wales, 1968–1985. BMJ 1990;300:173–4.
Kanis JA, Adami S. Bone loss in the elderly. Osteoporosis Int 1994 (in press).
Hansen M, Overgaard K, Riis B, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991;303:961–4.
Falch JA, Sandvik L. Perimenopausal appendicular bone loss: a ten-year prospective study. Bone 1990;11:425–8.
Christiansen C, Riis BJ, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987;1:1105–8.
Hui SL, Wiske PS, Norton JA, Johnston CC J. A prospective study of change in bone mass with age in postmenopausal women. J Chron Dis 1982;35:715–25.
Aaron JE, Makins NB, Sagreiya K. The microanatomy of trabecular bone loss in normal ageing men and women. Clin Orthop 1987;215:260–71.
Parfitt AM, Mathews CHE, Villaneuva AR, Kleerkoper M, Frame B, Rao DS. Relationships between surface volume and thickness of iliac trabecular bone in ageing and osteoporosis. J Clin Invest 1983;72:1396.
Parfitt AM. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am J Med 1987;82:68–72.
Krolner B, Pors Nielsen S. Bone mineral content of the lumbar spine in normal and osteoporotic women: cross-sectional and longitudinal studies. Clin Sci 1982;62:329–36.
Firooznia H, Sloutskis D, Anderson JJ, Anthony JM, Kiel DP. Quantitative computed tomography assessment of spinal trabecular bone. II. In osteoporotic women with and without vertebral fractures. J Comput Assist Tomogr 1984;8:99–103.
Chevalley T, Rizzoli R, Nydegger V, Slosman D, Tkatch L, Rapin CH, Vasey H, Bonjour J-P. Preferential low bone mineral density of the femoral head in patients with a recent fracture of the proximal femur. Osteoporosis Int 1991;1:147–54.
Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:1804–9.
Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, et al. and the Study of Osteoporotic Fractures Research Group. Appendicular bone density and age predict hip fracture in women. JAMA 1990;263:665–8.
Wasnich RD, Ross PD, Davis JW, Vogel JM. A comparison of single and multi-site BMC measurements for assessment of spine fracture probability. J Nucl Med 1989;30:1166–71.
Wasnich RD, Ross PD, Davis JW, Vogel JM. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 1985;153:745–51.
Wasnich RD, Ross PD, MacLean CJ, Davis JW, Vogel JM. The relative strengths of osteoporotic risk factors in a prospective study of postmenopausal osteoporosis. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis vol. 1. 1984, Glostrup Hospital, Glostrup, Denmark, 394–5.
Wasnich RD, Ross PD, Vogel JM, Davis JW. Osteoporosis: critique and practicum. Honolulu, Hawaii: Banyan Press, 1989.
Lips P, Obrant KJ. The pathogenesis and treatment of hip fractures. Osteoporosis Int 1991;1:218–31.
Cooper C, Barker DJP, Morris J, Briggs RSJ. Osteoporosis, falls, and age in fracture of the proximal femur. BMJ 1987;295:13–5.
Cummings SR. Bone mass and bone loss in the elderly: a special case. In: Christiansen C, Riis B, editors. Fourth International Symposium on Osteoporosis. Redovre, Denmark, 1993:499–500.
Cameron JR, Mazess RB, Sorenson MS. Precision and accuracy of bone mineral determination by direct photon absorptiometry. Invest Radiol 1968;3:141–50.
Chestnut CH. Noninvasive techniques in the diagnosis of osteoporosis. Presented at the NIH Consensus Development Conference on Osteoporosis, 1984.
Gotfredsen A, Harsager C, Christiansen C. Total and regional bone mass in healthy and osteoporotic women. In: Yakamura S, editor. Advances in in vivo body composition studies. New York; Pleum Press 1990:101–6.
Hansen MA, Hassager C, Overgaard K, Marslew U, Riis BJ, Christiansen C. Dual-energy X-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spine. J Nucl Med 1990;31:1156–62.
Kanis JA, McCloskey EV, Eyres KS, O'Doherty DV, Aaron JE. Screening techniques in the evaluation of osteoporosis. In: Drife JO, Studd JWW, editors. HRT and osteoporosis. Berlin: Springer, 1990:135–47.
Kanis JA, Caulin F, Russell RGG. Problems in the design of clinical trials in osteoporosis. In: Dixon A St J, Russell RGG, Stamp TCB, editors. Osteoporosis: a multidisciplinary problem. Royal Society of Medicine International Congress Symposium Series 55, Royal Society of Medicines, London 1983:205–22.
Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. and the Study of Osteoporotic Fractures Research Group. Bone density and hip fractures in older women: a prospective study. Lancet 1992;341:72–5.
Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23.
Black DJ, Cummings SR, Melton LJ III. Appendicular bone mineral and a woman's lifetime risk of hip fracture. J Bone Miner Res 1992;7:639–46.
Smith DM, Khairi MRA, Johnston CC. The loss of bone mineral with aging and its relationship to risk fracture. J Clin Invest 1975;56:311–8.
Cleghorn DB, Polley KJ, Bellon MJ, Chatterton J, Baghurst PA, Nordin BEC. Fracture rates as a function of forearm mineral density in normal postmenopausal women: retrospective and prospective data. Calcif Tissue Int 1991;49:161–3.
Hui SL, Slemenda CW, Johnston CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989;111:355–61.
Nordin BEC, Need AG, Chatterton BE, Horowitz M, Cleghorn DB. Bone density screening for osteoporosis. Lancet 1990;336:1327–8.
Ross PD, Wasnich RD, Heilbrun LK, Vogel JM. Definition of a spine fracture threshold based upon prospective fracture risk. Bone 1987;8:271–8.
Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–33.
Gardsell P, Johnell O, Nilsson BE. Predicting fractures in women by using forearm bone densitometry. Calcif Tissue Int 1989;44:235–42.
Gardsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif Tissue Int 1991;49:90–4.
Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease: overall findings and differences by age for 316099 white men. Arch Intern Med 1992;152:56–64.
Khaw K, Barrett-Connor E, Suarez L, Crique MH. Predictors of stroke associated mortality in the elderly. Stroke 1984;15:244–8.
Wilson JMG, Jungner G. Principles and practice of screening for disease. WHO Public Health Paper no. 34. Geneva: World Health Organization, 1968.
Kanis JA. Screening for postmenopausal osteoporosis: a review for the Department of Health, UK, 1992.
Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878–83.
Geusens P, Dequeker J, Verstraeten A, Nijs J. Age, sex and menopause related changes of vertebral and peripheral bone: population study using dual and single photon absorptiometry and radiogrammetry. J Nucl Med 1986;27:1540–9.
Nilas L, Gotfredsen A, Riis BJ, Christiansen C. The diagnostic validity of local and total bone mineral measurements in postmenopausal osteoporosis and osteoarthritis. Clin Endocrinol 1986;25:711–20.
Devogelaer JP, Depresseux G, Nagant de Deuxchaisnes C. Reproducibility of single photon absorptiometry by rectilinear forearm scanning at three sites. In: Dequeker J, Geusens P, Wahner HW, editors. Bone mineral measurement by photon absorptiometry. Leuven: Leuven University Press, 1988:215–9.
Kollerup G, Sorensen HA. Bone mass in the forearm by dual photon energy X-ray absorptiometry. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:736–8.
Garn SM, Sullivan TV, Decker SA, Larkin FA, Hawthorne VM. Continuing bone expansion and increasing bone loss over a two-decade period in men and women from a total community sample. Am J Hum Biol 1994 (in press).
Hui SL, Slemenda CW, Johnston CC. The contribution of bone loss to postmenopausal osteoporosis. Osteoporosis Int 1990;1:30–4.
Stepan JJ, Pospichal J, Schreiber V, Kanka J, Mensik J, Presl J, Pacovsky V. The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen and norethisterone. Calcif Tissue Int 1989;45:273–80.
Crilly RG, Jones MM, Horsman A, Nordin BEC. Rise in plasma alkaline phosphatase at the menopause. Clin Sci 1980;58:341–2.
Christiansen C, Riis BJ, Nilas L, Rodbro P, Deftos L, Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985;2:800–1.
Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of bone remodelling in surgically induced postmenopausal women. Bone 1987;8:279–84.
Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990;19:1–18.
Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988;18:191–5.
Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367–73.
Horsman A, Birchall MN. Assessment and modification of hip fracture risk: predictions of a stochastic model. In: DeLuca HF, Mazess R, editors. Osteoporosis: physiological basis, assessment and treatment. New York: Elsevier, 1990:45–50.
Trotter MN, Broman GE, Peterson RR. Densities of bones of white and negro skeletons. J Bone Joint Surg [Am] 1960;42:50–8.
Nordin BEC, MacGregor J, Smith DA. The incidence of osteoporosis in normal women: its relation to age and the menopause. Q J Med 1966;137:25–8.
Sowers MR, Wallace RD, Lemke JH. Correlates of mid-radius bone density among postmenopausal women: a community study. Am J Clin Nutr 1985;41:1045–53.
Evers SE, Orchard JW, Haddad RG. Bone density in postmenopausal North American Indians and Caucasian females. Hum Biol 1985;57:719–26.
Dequeker J, Tobing L, Rutten V, Geusens P, Medos Study Group. Relative risk factors for osteoporotic fracture: a pilot study of the MEDOS questionnaire. Clin Rheumatol 1991;10:49–53.
Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363–9.
Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis. BMJ 1989;298:924–8.
Laitinen K, Valimaki M, Keto P. Bone mineral density measured by dual-energy X-ray absorptiometry in healthy Finnish women. Calcif Tissue Int 1991;48:224–31.
Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. J Bone Miner Res 1991;6:331–8.
Aloia JF, Vaswani AN, Yeh JK, Ross P, Ellis K, Cohn SH. Determinants of bone mass in postmenopausal women. Arch Intern Med 1983;143:1700–4.
Bauer DC, Browner WS, Cauley JA, Orwoll ES, Scott JC, Black DM, et al. for the Study of Osteoporotic Fractures Research Group. Factors associated with appendicular bone mass in older women. Ann Intern Med 1993;118:657–75.
Cooper C, Atkinson EJ, Wahner HW, O'Fallon WM, Riggs BL, Judd HL, Melton LJ III. Is caffeine consumption a risk factor for osteoporosis? J Bone Miner Res 1992;7:465–71.
Elliott CA, Price VH, Wallace WA. The predictive value of radial and hip fracture for further fracture risk in Nottingham. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:216–7.
Johnston CC, Melton LJ, Lindsay R, Eddy DM. Clinical indications for bone mass measurements. Report of scientific advisory committee of the National Osteoporosis Foundation. Bone Miner Res 1989;4 (Suppl 2):1–28.
Slemenda CW, Hui SL, Longscope C, Wellman H, Johnston CC. Predictors of bone mass in perimenopausal women: a prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990;112:96–101.
van Hemert AM. Epidemiology of osteoporosis and prediction of fractures: a nine-year population based follow up. Thesis, Erasmus University of Rotterdam, 1989.
Citron JT, Ettinger B, Genant HK. Prediction of peak premeno-pausal bone mass using a scale of weighted clinical variables. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis 1987, vol. 1. Denmark: Norhaven, 1987:146–9.
Elders PJM, Netelenbos JC, Lips P, Khoe E, van Ginkil FC, Hulshof KFAM, van der Stelt PV. Perimenopausal bone mass and risk factors. Bone Miner 1989;7:289–99.
Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J, Eisman J. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993;307:1111–5.
Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskovitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med 1987;317:1169–74.
Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;95:28–31.
Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37.
Naessen T, Parker R, Persson I, Zack M, Adami H-O. Time trends in incidence rates of first hip fracture in the Uppsala health care region, Sweden, 1965–1983. Am J Epidemiol 1989;130:289–99.
Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. Hormone replacement therapy in the menopause: an analysis of benefits, risks and costs. Report to the Department of Health, UK, 1991.
Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J. Bone response to termination of oestrogen treatment. Lancet 1978;1:1325–7.
Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459–61.
Stevenson JC, Kanis JA, Christiansen C. Bone density measurement. Lancet 1992;339:370–1.
Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991;338:355–8.
Johansson C. Osteoporosis in the elderly. MD thesis, University of Goteborg, 1993.
Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67–72.
Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zank MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985–90.
Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825–32.
Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progesterone replacement therapy. Am J Epidemiol 1989;130:221–8.
Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861–7.
Cauley J, Cummings SR, Black DM, Mascioli SR, Seeley DG, Prevalence and determinants of estrogen replacement therapy in elderly women. Am Obstet Gynecol 1990;163:1438–44.
Egeland G, Kuller L, Matthews K, Kelsey S, Cauley J, Guzick D. Premenopausal determinants of menopausal estrogen use. Preventive Med 1991;20:343–9.
Vandenbroucke JP. Postmenopausal oestrogen and cardiopro-tection. Lancet 1991;337:833–4.
Nachtigall L, Nachtigall RH, Nachtigall RD, Beckman EM, Estrogen replacement therapy. II. A prospective study in the relationship in carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–9.
Persson I, Falkeborn M, Lithell H. The effect of myocardial infarction (MI) risk of estrogens and estrogen-progestin combinations. In: Sixth international congress on the menopause. Bangkok: Parthenon Publishing Group, 1990:223.
Tosteson ANA, Rosenthal DI, Melton LJ, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594–603.
Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–8.
Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis. Am J Med 1986;80:1115–27.
Chapuy MC, Arlot ME, Duboeuf F, Brun J, Cronzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637–42.
Dawson-Hughes B. Calcium supplementation and bone loss: a review of controlled clinical trials. Am J Clin Nutr 1991;54:274S-280S.
Elders PJM, Netelenbos JC, Lips P, van Ginkel FC, Khoe E, Leeuwenkamp OR, Hackeng WHL, van der Stelt PF. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. J Clin Endocrinol Metab 1991;73:533–40.
Kanis JA, Johnell O, Gullberg B, Allander E, Dilzen G, Gennari C, et al. Evidence for the efficacy of bone active drugs in the prevention of hip fracture. BMJ 1992;305:1124–8.
Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–9.
Reginster JY, Denis D, Albert A, et al. One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;2:1481–3.
Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;2:1469–71.
Overgaard K, Hansen MA, Nielsen V-AH, Riis BJ, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990;89:1–6.
Peyron R, Serrurier D, Edouard C, Ghozlan R, Mayoux-Benhamou A, Meunier PJ. Treatment of high remodelling vertebral osteoporosis with human calcitonin: a two-year double blind placebo-controlled trial in 93 patients. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:1430–2.
Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556–61.
Orimo H, Shiraki M, Hayashi T, Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with l(OH)-vitamin D3. Bone Miner 1987;3:47–52.
Tilyard M, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–62.
Felson DT, Sloutskis D, Anderson JJ, Anthony JM, Kiel DP. Thiazide diuretics and the risk of hip fracture. JAMA 1991;265:370–3.
LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA. George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990;322:286–90.
Ray WA. Long term use of thiazide diuretics and the risk of hip fracture. Lancet 1989;1:687–90.
Kanis JA, Beneton MNC, Gennari C, Gullberg B, Johnell O, Mazzuoli GF, Passeri M. Effects of anabolic steroids on cortical bone and fractures. In: Christiansen C, Riis B, editors. Fourth international symposium on osteoporosis. Redovra: Denmark, 1993:308–10.
Riggs BL, Hodgson SF, O'Fallon WM, Chao Eys, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;22:802–9.
Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Safe and effective treatment of osteoporosis and intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 1989;68:150–9.
Kanis JA, Meunier PJ, Should we use fluoride to treat osteoporosis? Q J Med 1984;53:145–64.
Mamelle N, Meunier PJ, Dusan R, Guilaume M, Martin JL, Gaucher A, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361–5.
Cummings SR, Black D. Should perimenopausal women be screened for osteoporosis? Ann Intern Med 1986;104:817–23.
Suman VJ, Atkinson EJ, O'Fallon WM, Black DM, Melton LJ. A nomogram for predicting lifetime hip fracture risk from radius bone mineral density and age. Bone 1993;14:843–6.
Cuckle HS, Wald NJ. Principles of screening. In: Wald N, editor. Antenatal and neonatal screening. Oxford: Oxford University Press, 1984:1–22.
Cadman D, Chambers L, Feldman W, Sackett D. Assessing the effectiveness of community screening programmes. JAMA 1984;251:1580.
See Appendix for a list of members of the WHO Study Group.
About this article
Cite this article
Kanis, J.A., Kanis, J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. Osteoporosis Int 4, 368–381 (1994). https://doi.org/10.1007/BF01622200